As guided through the course of the year, FY26 was envisaged as a year of consolidation for the Company, and the results of the year reflect that. Whilst the headline financial performance does not show significant growth, the business has become structurally and fundamentally stronger, and is now well placed for healthy growth in the years ahead. We have utilised the year gone by to deepen the foundations of the business, securing critical approvals, advancing work on newer and more innovative molecules, and meaningfully building up both our capabilities and capacities. I am please to report that we are making strong progress on our CRAMS engagements across agrochemicals, pharmaceuticals and electronic applications, with active projects spanning Europe and Japan. We have achieved significant milestones on these mandates, and I am delighted to share that the pilot trials for these projects have been successfully completed during Q4FY26. We will now move into the commercial trial phase, and subject to the requisite customer and regulatory approvals, we expect to commence commercial production of these molecules thereafter. This represents an important inflection point for our specialty and contract manufacturing platform. On the capacity front, our Block 7 expansion programme remains firmly on track, and we now expect commercial production to commence from Q2FY27. This additional capacity is being purposefully built to support our pipeline of niche, application-led molecules and will play a meaningful role in driving the next phase of growth. The broader operating environment has, admittedly, continued to remain challenging. The slowdown in Europe has persisted, the ongoing war situation has introduced further uncertainty, raw material markets have witnessed considerable volatility, and a number of customers have deferred purchases amidst this backdrop. Against these headwinds, I believe our performance reflects a measure of resilience. We have remained steadfast in our strategic focus on building a robust platform, concentrating on niche applications where competitive intensity is limited and where the runway for differentiated growth is meaningful. Whilst this path may appear measured in pace, we firmly believe it is the right approach to create a more sustainable and profitable business over the long term. Looking ahead, we remain confident and well prepared to deliver improving growth and profitability in the coming years. With the pilot facility now fully operational, Block 7 nearing commissioning, our CRAMS projects moving from pilot to commercial stage, and a stronger product development pipeline, the Company is poised for growth.